RBM20

RBM20 (also associated with the PRIMYO platform) is a personalized mRNA-based cancer vaccine being developed by myNEO Therapeutics for the treatment of solid tumors. The vaccine utilizes myNEO's proprietary "camyotope" technology to identify novel, tumor-specific antigens derived from the "dark genome"—specifically non-coding regions like long non-coding RNAs (lncRNAs) that contain small open reading frames (smORFs). By encoding these patient-specific camyotopes into an mRNA delivery system, the vaccine aims to induce a robust MHC-I-restricted CD8+ T-cell immune response against the tumor. The program is currently in the discovery stage and focuses on leveraging cryptic peptides that are not typically targeted by traditional neoantigen vaccines.

Other names

personalized camyotope mRNA vaccinemyNEO personalized mRNA vaccine